- Home
- ASTL vs OPT Comparison
ASTL vs OPT Comparison
Compare ASTL & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTL
- OPT
- Stock Information
- Founded
- ASTL 1902
- OPT 1984
- Country
- ASTL Canada
- OPT Australia
- Employees
- ASTL N/A
- OPT 34
- Industry
- ASTL Steel/Iron Ore
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASTL Industrials
- OPT Health Care
- Exchange
- ASTL Nasdaq
- OPT Nasdaq
- Market Cap
- ASTL 868.8M
- OPT 472.5M
- IPO Year
- ASTL N/A
- OPT 2020
- Fundamental
- Price
- ASTL $6.24
- OPT $3.11
- Analyst Decision
- ASTL
- OPT Strong Buy
- Analyst Count
- ASTL 0
- OPT 1
- Target Price
- ASTL N/A
- OPT $12.00
- AVG Volume (30 Days)
- ASTL 1.5M
- OPT 38.8K
- Earning Date
- ASTL 03-12-2025
- OPT 02-28-2025
- Dividend Yield
- ASTL 3.21%
- OPT N/A
- EPS Growth
- ASTL N/A
- OPT N/A
- EPS
- ASTL N/A
- OPT N/A
- Revenue
- ASTL $1,706,096,151.00
- OPT $208,859.00
- Revenue This Year
- ASTL N/A
- OPT N/A
- Revenue Next Year
- ASTL $13.28
- OPT $46,864.64
- P/E Ratio
- ASTL N/A
- OPT N/A
- Revenue Growth
- ASTL N/A
- OPT N/A
- 52 Week Low
- ASTL $5.20
- OPT $1.79
- 52 Week High
- ASTL $12.14
- OPT $6.30
- Technical
- Relative Strength Index (RSI)
- ASTL 36.91
- OPT 32.70
- Support Level
- ASTL $5.20
- OPT $3.06
- Resistance Level
- ASTL $6.93
- OPT $3.52
- Average True Range (ATR)
- ASTL 0.47
- OPT 0.54
- MACD
- ASTL -0.07
- OPT -0.18
- Stochastic Oscillator
- ASTL 42.22
- OPT 2.99
About ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a Canadian company engaged in the production of clean and consistent light gauge steel. The company offers a range of hot and cold rolled steel sheet and plate products. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.